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ABSTRACT 
Objective: The aim of this study was to formulate and in vitro evaluate fast dissolving oral film of practically insoluble bromocriptine mesylate to 
enhance its solubility and to improve its oral bioavailability by avoiding first pass effect as well as to produce an immediate release action of the 
drug from the film for an efficient management of diabetes mellitus type II in addition to an improvement of the patient compliance to this patient-
friendly dosage form. 
Methods: The films were prepared by the solvent casting method using hydroxypropyl methylcellulose of grades (E3, E5, E15), polyvinyl alcohol 
(PVA), pectin and gelatin as film-forming polymers in addition to polyethene glycol 400 (PEG400), propylene glycol (PG) and glycerin were used as 
a plasticizer. Poloxamer 407 was used as a surfactant, sodium saccharin as a sweetening agent, citric acid as a saliva stimulating agent, vanilla as a 
flavouring agent and crospovidone as a super disintegrant. The prepared films then tested for physical characterization, thickness, weight 
uniformity, mechanical characteristics (folding endurance, tensile strength, percent elongation and Young's modulus), surface pH, in vitro 
disintegration time, drug content and an in vitro drug release.  
Results: Films were found to be satisfactory when evaluated for physical characterization, thickness, weight uniformity, mechanical tests, in vitro 
disintegration time, folding endurance, drug content and an in vitro drug release. The surface pH of all the films was found to be neutral or minor 
change. Films in vitro drug release studies were also done using USP dissolution apparatus type II (paddle type). The in vitro drug release profile in 
the optimized formulation F14 was gave 86.8 % of drug released at 2 min. The optimized formulation F14 was also showed satisfactory pH 
(6.2±0.2), drug content (99.2±0.5%), the disintegration time of 9.2±0.1 seconds and the time needed for 80% of medication to be released (T80 %) 
was 1.35 minute. 
Conclusion: The bromocriptine mesylate fast dissolving oral film was formulated. The given film disintegrates within nine seconds which release 
the drug rapidly and gives an action. 
Keywords: Bromocriptine mesylate, Fast dissolving oral film, Solvent casting method 




Among all routes of drug administration, the oral route is one of the 
most favored routes, as it is more convenient, cost-effective, and 
ease of administration lead to high level of patient compliance, but 
the problem associated with this route is the swallowing difficulty 
for pediatric and geriatric patients who have a fear of choking. In 
addition to that, patient convenience and compliance-oriented 
research have resulted in present safer and newer drug delivery 
systems [1]. 
Buccal drug delivery recently becomes an important route of drug 
administration in which problems like high first-pass metabolism 
and drug degradation in the gastrointestinal environment can be 
avoided by administering the drug through buccal route [2]. 
Drug delivery via the oral mucosa is a promising route when one 
wishes to achieve a rapid onset of action or an improved 
bioavailability for drugs which have a high first-pass metabolism. 
Thus, fast dissolving films allow the films to dissolve in the mouth, 
so the drug gets directly absorbed into the systemic circulation 
through the oral mucosa [3]. 
Oral fast dissolving films (OFDFs) are the most advanced form of an 
oral solid dosage form. These are solid dosage forms, which 
disintegrate or dissolve within a minute when placed in the mouth 
without drinking water or chewing. The oral films are formulated 
using polymers, plasticizer, flavors, colors, and sweeteners. OFDFs 
are prepared using hydrophilic polymers that rapidly dissolves in 
the oral cavity delivering the drug to the systemic circulation. Water-
soluble polymers are used in OFDFs as they achieve rapid 
disintegration. Plasticizer helps to enhance the flexibility of the strip 
and reduces the brittleness of the strip [4]. 
The films are intended to place in the buccal cavity, and fewer doses 
are required which improves the patient compliance. Stability of the 
dosage form can also be enhanced when formulated as a film. Also, 
the ODF is a solid unit dosage form provides an accurate dosing and 
a great precision [5]. 
Bromocriptine is a semisynthetic ergot alkaloid that interacts with 
D2 dopamine receptors to inhibit spontaneous and TRH-induced 
release of prolactin. It is used in neuroleptic malignant syndrome, 
acromegaly, infertility, hyperprolactinemia, prolactinoma, 
Parkinson’s disease, and type 2 diabetes mellitus. It was approved 
by the Food and Drug Administration (FDA) in May 2009, for the 
treatment of type 2 diabetes [6]. 
Bromocriptine mesylate is rapidly absorbed, after oral 
administration, the bioavailability of the drug is 28% of the oral dose 
consumed, and the plasma protein binding amounts to 96%. It is 
highly distributed in the liver, stomach, and intestine. The drug is 
extensively metabolized in the liver. The fate of bromocriptine 
mesylate primarily involves with renal excretion of two major 
metabolites accounting for 6% of the total dose. The elimination of 
the parent drug from the plasma is biphasic with a terminal half-life 
of 15 h. Bromocriptine mesylate stimulates dopamine type-II 
receptors and antagonizes type-I receptors in the hypothalamus and 
neostriatum of the CNS [7]. 
Bromocriptine mesylate acts centrally as an antidiabetic agent by a 
novel mechanism and reduces plasma glucose, triglycerides, free 
Fatty Acid (FFA) levels, and possibly cardiovascular events [8]. 
The aim of this study was to formulate and in vitro evaluate a fast 
dissolving oral film of practically insoluble bromocriptine mesylate 
to enhance its solubility of drug and to improve its oral 
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bioavailability of drugs by avoiding first pass effect as well as to 
produce an immediate release action of drug from the film for an 
efficient management of diabetes mellitus type II in addition to an 
improvement of the patient compliance to this patient-friendly 
dosage form. 
MATERIALS AND METHODS 
Material 
Bromocriptine mesylate was purchased from Avril Chemical 
Limited, China. HPMC E3, E5, E15, PVA, pectin and gelatin was 
purchased from Hangzhou Hyper Chemical Limited, China. 
Poloxamer 407 was purchased from Hangzhou Hyper Chemical 
Limited, China. PEG400, glycerin was purchased from Fluka 
Chemical AG, Switzerland. Propylene glycol was purchased from 
Evans Medical Ltd, Liverpool, England. All other chemicals and 
solvents were of analytical reagent grade, and deionized water also 
was used in this study. 
Method 
Determination of λ max 
10 mg of bromocriptine mesylate was dissolved in100 ml of 0.1 N 
HCl (pH 1.2) and phosphate buffers (pH 6.8) with (0.5% w/v Brij-
35) individually to make a stock solution of concentration (0.1 
mg/ml). Then From this prepared stock solution, a diluted solution 
(0.065 mg/ml) was established and determined the λmax of 
bromocriptine mesylate using UV spectrophotometric analysis at 
200-400 nm. 
Construction of calibration curves 
Calibration curves for bromocriptine mesylate in 0.1 N HCl and 
phosphate buffers (pH 6.8) with (0.5% w/v Brij-35) were made by 
preparing consecutive dilutions of the drug from a stock solution 
(0.1 mg/ml), samples (65, 55, 45, 35, 25 and 15 µg/ml) were then 
analyzed by spectrophotometric method for bromocriptine mesylate 
at its λ max (305 nm) [7]. 
Determination of saturation solubility of bromocriptine 
mesylate 
The solubility of Bromocriptine Mesylate was determined by 
dissolving the excess amount of drug in different medium 0.1N HCl, 
phosphate buffer(pH 6.8) and phosphate buffer (pH 6.8) containing 
0.5% w/v Brij-35) at room temperature and kept for 48h with 
regular shaking. The solutions were centrifuged then filtered and 
examined by using UV-spectrophotometer at its λ max, and from this 
absorbance, the concentration of that saturated solution was 
determined which represents the solubility of bromocriptine 
mesylate in these solutions.  
Method for preparation of fast dissolving oral film of 
bromocriptine mesylate 
Fourteen formulas were prepared (F1-F14) as listed in (table 1) by 
using solvent casting technique; every film of about 4 cm2 area must 
contain 0.8 mg of bromocriptine mesylate. The size and number of 
films that formulated for every group designed as the following:  
Each film with an area of 4 cm2 (2 cm ×2 cm) and contain 0.8 mg of 
bromocriptine mesylate.  
The amount of drug in the film was calculated as follows:  
The dose of the drug to be incorporated in each 4 cm2 film = 0.8 mg 
of bromocriptine mesylate. 
Diameter of petri dish = 11 cm, so that the radius = 5.5 cm. 
Area of Petri dish = π r2 = 3.14 × (5.5 cm)2 = 94.985 cm2 
approximately =95 cm2. 
Number of 4 cm2 films obtained from main film =95 cm2 ÷ 4 cm2 = 
23.75 films approximately = 24 films each with area 4 cm2. 
Amount of drug in the area considered = 24 film × 0.8 mg =19.2 mg 
The fast-dissolving oral films of bromocriptine mesylate were 
prepared by solvent casting method using: hydroxypropyl 
methylcellulose (HPMC) with different grades like HPMC E3, E5, and 
E15, and another type of hydrophilic polymers as the film-forming 
polymers, PEG 400, propylene glycol (PG) and glycerin were used as 
plasticizer, poloxamer 407 as a surfactant, citric acid as a saliva 
stimulating agent, sodium saccharin as a sweetening agent, vanilla as 
a flavoring agent and crospovidone as a super disintegrant. The 
considered quantity of film-forming polymer was dissolved in 20 ml of 
solvent (distilled water) with constant stirring by using magnetic 
stirrer for two h to form a homogenous polymeric solution. To this 
polymeric solution, a suitable amount of plasticizer was added with a 
continuous stirring for another one h. The next step was that, the drug 
(bromocriptine mesylate), surfactant, saliva stimulating agent and 
sweetener were dissolved in 10 ml of water and ethanol as a co-
solvent (5 ml water+5 ml ethanol) in another beaker to form clear 
solution, mix the two solutions using magnetic stirrer for one hour, the 
solution was kept in a sonicator for degassing. Then the bubble free 
solution was cast on to a petri dish with a diameter of 11 cm2 and kept 
in hot air oven (60 °C) overnight. The dried film was then removed and 
cut into the desired shape and size (2 cm × 2 cm) for the intended 
application. Cuts or defectiveness were omitted from the study [9]. 
  
Table 1: Composition of bromocriptine mesylate oral films formulas 
Ingredients present 
in each film (mg) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
Bromocriptine 
mesylate 
0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 
HPMC E3  25              
HPMC E5   25     27.5 30 25 25 25 25 25 25 
HPMC E15    25            
Polyvinyl alcohol    25           
Pectin     25          
Gelatin      25         
Polyethylene glycol 
400 
10 10 10 10 10 10 10 10   7.5 12.5 12.5 12.5 
Propylene glycol          10      
Glycerin           10     
Poloxamer 407 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Crospovidone             0.5 1.5 
Citric acid  2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Vanilla  2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Sodium saccharin  2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
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Evaluation of fast dissolving oral film of bromocriptine 
mesylate 
Physical characterization of the prepared films 
Physical characterization can be carried out by visual inspection for 
characteristics such as color, thickness, brittleness, peeling ability, 
transparency, surface smoothness, tack property and film-forming 
capacity [10]. 
Weight variation 
Weight variation test confirms the uniformity of the film formed. 
Ten randomly selected films from each patch (each of 2 cm × 2 cm) 
were cut and weighed individually and matched with the mean 
weight for deviation [11]. 
Thickness measurements 
Film thicknesses were determined using the Digimatic and Vernier 
Caliper. Each wafer was measured at five positions (central and the four 
corners) the mean thickness was calculated. This test was performed on 
six films of each formulation and mean±S. D calculated [12]. 
Drug content uniformity 
This test was done by using the procedure described in United 
States Pharmacopoeia in which a solvent solution was prepared by 
dissolving 1g of tartaric acid in 500 ml of water, then 500 ml of 
methanol was added with mixing. 
A standard solution was prepared, which consists of bromocriptine 
mesylate, dissolved in the solvent solution at a concentration of 0.04 
mg/ml. 
The test solution was prepared by transferring a tablet, for which 
the drug content to be determined, into a volumetric flask contains 
the 15 ml solvent solution. It was shaken mechanically for 30 min 
then diluted with the solvent solution up to 25 ml with mixing, after 
filtration, 10 ml of the clear filtrate was diluted to 50 ml. 
Then the following equation was utilized to determine the film 
content of bromocriptine mesylate:  
Bromocriptine mesylate content in mg = (TC/D)(At/As) 
In which T is the labeled quantity, in mg, of bromocriptine mesylate 
in the film, C is the concentration, in microgram per ml, of 
bromocriptine mesylate in the standard solution, D is the 
concentration in microgram per ml, of bromocriptine in the solution 
from the film, based upon the labeled quantity in the film and the 
extent of dilution, while At and As are the absorbance of the solution 
from the film and the standard solution [13]. 
Determination of surface pH  
The determination of surface pH is important to investigate 
opportunity of any side effects when using the ODFs in vivo, because 
the acidic or basic pH may irritate the mucosal membrane of an oral 
cavity. To measure the pH value of ODF one strip was allowed to 
dissolve in 2 ml of distilled water and the PH of the obtained 
solution is determined using pH-meter.  
Different pH value will be expected because of the fact of using a 
different film forming polymers in the formulation of ODFs along 
with the drug [14]. 
Folding endurance 
Folding endurance is measured by manual repeated folding of the 
film at the same place till it broke. The number of time the film is 
folded without breaking is known as the folding endurance value. A 
strip of 2 × 2 cm diameter (an area of 4 cm2) was subjected to 
folding endurance by folding the film at the same place repeatedly 
several times until a visible crack was observed, and the average 
values were calculated and reported. Folding endurance more than 
300 indicating that the formulation good tough and flexible [15, 16]. 
Tensile strength 
It is the maximum value of forces applied to the film at which its 
breakdowns. The tensile strength was determined by way of holding 
a film of 5 cm × 2 cm (which must be pure from air bubbles or any 
physical defectiveness and cut as dumbbell-shaped) longitudinally in 
the tensometer, Then the ODFs were drawn at a level of 10 mm/min. 
The tensile strength was measured mathematically by dividing the 
applied force at which the film is broken by the cross-section area of 
the stripe and was expressed in force per unit area: mega Pascal 
(MPa) as shown in the following equation [16]. 
Tensile Strength = Load to Break/Width × Thickness × 100 
Percent of elongation 
When stress is applied the film sample stretches and is referred to as 
strain. The strain is the deformation of the film divided by the 
original dimension of the film. Elongation of the film increases as the 
plasticizer concentration increases. Percentage elongation was 
calculated by measuring the increase in the length of the film after 
tensile strength measurement by using the following formula [17]: 
Percentage Elongation = [Final length-initial length] X 100/initial length 
Young's modulus (YM) 
Young's modulus or elastic modulus is the measure of the stiffness of 
strip. It is represented as the ratio of applied stress over strain in the 
region of elastic deformation as follows:  
Young’s modulus = Slope X 100/Strip thickness X Cross-head speed 
Hard and brittle strips demonstrate a high tensile strength and 
Young's modulus with small elongation [18]. 
Percent moisture loss (PML)  
The films were weighed accurately and kept in a desiccator 
containing anhydrous calcium chloride. After three days the films 
were taken out and weighed. The moisture loss was calculated using 
the formula [19]: 
 
Percent moisture absorb (PMA) 
This test was carried out to check the physical stability of films at high 
humid conditions. In the present study, the moisture absorption 
capacity of the bromocriptine mesylate fast dissolving films were 
determined by keeping the pre-weighed films in the desiccator 
containing a saturated solution of potassium chloride, which maintains 
79.5% relative humidity at room temperature for 72 h. Average 
percentage moisture absorption of three films can be calculated by the 
following equation [20]:  
 
In vitro disintegration time (DT) 
DT is the time at which the fast dissolving oral films start to break 
down or disintegrate (in second). The in vitro DT is measured by using 
petri dish method. The test is done by taking three films of each patch 
in a petri dish, and after adding 2 ml of distilled water for each film, the 
petri-dish was shaken continuously, then measure the time at which 
the ODFs start to break down or disintegrate. The determination of DT 
was done in triplicate for all the formulations [21].  
In vitro dissolution study 
The dissolution study was carried out using USP type II (paddle 
apparatus) with 300 ml of Phosphate buffer pH 6.8 with (0.5% w/v 
Brij-35) as a dissolution medium maintained at 37±0.5 °C. The 
medium was stirred at 50 rpm for 30 min. Samples were withdrawn 
by using a syringe at regular intervals (1, 2, 3, 4, 5, 10, 15 and 20 min) 
replaced with fresh medium in order to maintain sink conditions; 
before analyzing the withdrawn samples using UV-spectrophotometry 
at λmax 305 nm they must be filtered by using filter syringe (0.45μm).  
Samples were suitably diluted with the dissolution media and 
analyzed for the drug content at 305 nm. Cumulative percent drug 
release of bromocriptine mesylate was calculated and plotted 
against time [22]. 
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Drug-polymer compatibility study 
Fourier transform infrared spectroscopy (FTIR) 
The compatibility of the drug and the formulation was confirmed by 
IR spectra of pure drug and formulations that were determined by 
KBr disc method. 
Drug-polymer interactions were studied by FT-IR spectroscopy. The 
spectrum was recorded for the drug, blank polymer, the physical 
mixture of polymer and the drug in a ratio (1:1) and the selected 
formula. Samples were mixed with potassium bromide and pressed 
in the form of a disc. The disc was analyzed by FTIR spectroscopy 
from 4000-400 cm-1 [23]. 
X-ray powder diffraction (XRPD) 
Powder X-ray diffraction can be used to confirm the crystalline 
nature of materials. So, this information is used to verify whether 
the substances are crystalline or amorphous. The diffractograms 
of bromocriptine mesylate as a pure drug and the selected formula 
were obtained. The study was confirmed by using Shimadzu XRD-
6000 powder X-ray diffractometer at continuous scan range of 5 °-
80 ° of 2Ɵ The operating voltage was 40 (kV) and current 30mA 
[24]. 
Statistical analysis  
The results of the experiments are given as a mean of triplicate 
samples±standard deviation and were analyzed according to the one 
way analysis of variance (ANOVA) at the level of (P<0.05) to determine 
if the changes in the applied factors are statistically significant at level 
of (P ≤ 0.05) and non-significant at level of (p>0.05). 
RESULTS AND DISCUSSION  
Determination of λ max  
Scanning the diluted solutions of bromocriptine mesylate in 0.1N 
HCl and in pH 6.8 phosphate buffers with (0.5% w/v Brij-35) by 
using UV spectrophotometer at range of 200-400 nm provided the 
spectra revealed in (fig. 1-A and 1-B) respectively with the same 
peak for λmax at 305 nm as reported in reference [7]. 
Calibration curves of bromocriptine mesylate 
The constructed calibration curves of bromocriptine mesylate in 0.1 
N HCl (pH 1.2) and phosphate buffers (pH 6.8) With (0.5% w/v Brij-
35) are shown in (fig. 2-A and 2-B) respectively. A straight line was 
obtained by plotting the absorbance versus concentration with a 
high coefficient of determination. This indicates that the calibration 
curve obeys Beer’s law within the range of concentration used. 
 
 
Fig. 1: UV Spectrum of bromocriptine mesylate in A-0.1 N HCl (pH 1.2) B-phosphate buffers (pH 6.8) with (0.5% w/v Brij-35) 
 
 
A     B 
Fig. 2: Calibration curve of bromocriptine mesylate in A-0.1 N HCl (pH 1.2) B-phosphate buffers (pH 6.8) with 0.5% w/v Brij-35. (Results 
are expressed as mean, n=3) 
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Saturation solubility of bromocriptine mesylate 
The solubility of the drug at acidic pH was significantly higher than 
in that of buffer (pH 6.8), as shown in the table (2), this can reflect 
the alkaline nature of the drug. 
Bromocriptine mesylate is practically insoluble in water, so the addition 
of surfactant (Brij-35) can increase the solubility of bromocriptine 
mesylate by acting as an excellent solubilizing agent for the drug. It was 
found that 0.5 % of the Brij-35 act to increase the solubility of 
bromocriptine mesylate in buffer (pH 6.8) up to approximately six-fold. 
 
Table 2: Saturation solubility of bromocriptine mesylate in different media 
Solvent  PH 1.2 PH 6.8 PH6.8+0.5%brij 
Solubility(µg/ml) mean±SD* 160±0.11 24.7±0.5 158.88±0.3 
*SD standard deviation from mean, n=3 
 
Visual inspection 
All the prepared fast dissolving films showed homogenous and 
smooth surface properties which they contain (HPMC of grades E3, 
E5, E15), PVA, pectin, and Gelatin. 
Whereas HPMC and PVA films were transparent, colourless, thin and 
soft, those prepared from gelatin were thin, soft and semi-
transparent with yellowish color whereas pectin films turned to be 
opaque with brown color.  
Weight variation 
The outcomes reveal that: the average weights for all the prepared 
formulations were uniform and fit to the referred values as shown in 
the table (3), demonstrating that the strategy utilized for the 
preparation of films is reproducible and give films of uniform 
weight. The weight of the patches was determined using digital 
balance. All patches show consistency. 
Thickness 
The average thickness values of films for all formulas were shown in 
the table (3). The thickness was found to vary between 0.08±0.01 to 
0.12±0.02 mm. A very low standard deviation value is indicating that 
the method used for the formulation of films is reproducible and 
give films of uniform thickness and hence dosage accuracy in each 
film can be ensured. 
Drug content 
The formulated bromocriptine mesylate films showed an acceptable 
quantity of medicament ranged from 96.9±1.2 %-101.6±0.6 % as 
shown in the table (3). The accepted range of content uniformity 
labeled in BP is ranged from 85 % to 115 %, so the result of content 
uniformity is obeying this range this indicating that the solvent 
casting method used in preparing bromocriptine mesylate fast 
dissolving oral films is very efficient. On this basis, it was found that 
the drug was spread uniformly throughout the four cm² constant 
area of the films. 
Surface pH measurement 
All the prepared films showed an acceptable surface pH value 
(5.8±0.08-6.3±0.26) as viewed in the table (3) when compared to 
that pH of oral mucosa indicating that it does not irritate the oral 
mucosa. 
Percent moisture loss (PML) 
The moisture loss study gives an idea about nature, stability, and 
ability of films to retain its physicochemical properties under 
normal storage conditions. It also indicates hydrophilicity of films. 
All the obtained values are reported in the table (3). The obtained 
values were almost uniform and ranged from 0.7±0.5 % to 2.03±0.4 
% indicating little moisture loss and stable formulations. 
Percent moisture absorb (PMA) 
Moisture uptake study is an essential factor to be determined, as the 
presence of moisture bearings a critical investigation on drug 
stability. All the reported values of moisture uptake are listed in the 
table (3). It was detected that all the polymers were hydrophilic and 
the moisture absorbed values ranged from 1.35±0.6 % to 5.5±0.2%. 
Moisture uptake had an inverse relation to disintegration time, in 
another word as the moisture uptake increase the disintegration 
time decrease. 
 
Table 3: Physical evaluation parameters of bromocriptine mesylate fast dissolving films formulas 















F1 47.3±0.2 0.08±0.05 96.9±0.2 5.9±0.3 13.2±0.6 1.5±0.6 4.7±0.3 
F2 49.5±0.1 0.09±0.02 98.2±0.8 6.0±0.2 18.6±0.1 1.7±0.55 4.2±0.55 
F3 50.5±0.4 0.11±0.01 98.7±0.5 6.1±0.6 29±0.5 1.4±0.26 3.2±0.28 
F4 49.6±0.2 0.1±0.05 100.3±0.5 5.9±0.15 61±0.3 2.03±0.4 3.35±0.6 
F5 48.9±0.5 0.09±0.03 97.82±0.3 5.8±0.08 49.3±0.2 1.67±0.3 1.83±0.2 
F6 49.2±0.1 0.11±0.04 99.26±1.1 5.9±0.26 20.3±0.2 1.4±0.56 4.8±0.66 
F7 50.2±0.3 0.11±0.01 101.6±0.6 6.1±0.7 28.5±0.5 1.6±0.5 3.26±0.3 
F8 51.5±0.2 0.12±0.02 100.2±0.4 6.2±0.5 37.6±0.1 1.2±0.17 2.25±0.2 
F9 47.4±0.2 0.08±0.01 99.5±0.55 5.8±0.2 20±0. 2 1.7±0.37 2.6±0.6 
F10 48.9±0.1 0.08±0.02 98.8±0.62 6.0±0.45 19.5±0.6 1.2±0.25 2.9±0.45 
F11 49.7±0.05 0.09±0.05 98.66±0.5 6.3±0.26 24.2±0.1 1.8±0.16 3.5±0.32 
F12 50.8±0.1 0.1±0.03 99.98±1.2 6.2±0.5 14.5±0.6 0.7±0.5 5.4±0.25 
F13 49.5±0.09 0.1±0.02 99.2±0.5 6.2±0.5 11.5±0.2 1.6±0.3 5.3±0.32 
F14 49.5±0.1 0.09±0.02 99.2±0.5 6.2±0.2 9.2±0.8 1.25±0.1 5.5±0.32 
*n=3, **n=6, ***n=10, SD-standard deviation, DT-Disintegration time, PML-Percent moisture loss, PMA-Percent moisture absorb. 
 
Effect of different types of polymers 
Formulas (F1-F6) table (1) were utilized to study the effect of 
polymer type (HPMC E3, E5, E15, PVA, pectin, and gelatin) on the 
physical and mechanical properties of the prepared bromocriptine 
mesylate fast dissolving oral films and also their effect on the drug 
release profile. 
The mechanical properties of ODFs are essential since it related to 
their stability during storage, shipping, and packaging. 
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Tensile strength has been utilized as a marker of the general 
mechanical prevalence of the film. A high % elongation value shows 
that the film is tough and flexible. Folding endurance test results 
indicated that the films would maintain the integrity with buccal 
mucosa when applied and has good plasticity. This makes the 
system acceptable for movement of the mouth, indicating good 
strength and elasticity. The selected FDOFs must have reasonable 
tensile strength, a high percentage of elongation, low Young's 
modulus, short in vitro disintegration time and a high percent of 
drug release. 
The results in the table (3) showed that the lowest disintegration 
time of the film-forming polymer was HPMC E3 which represent 
(F1) with disintegration time of 13.2 sec.  
Different film forming-polymers gave different disintegration time 
value as shown in the fig. (3): 
 
Table 4: Mechanical properties of bromocriptine mesylate fast dissolving films formulas 
Formula code Folding endurance 
mean±SD 




F1 36±0.5 14.368±0.2 5.87±0.5 391.8±0.5 
F2 322±2.5 6.44±0.16 20.86±0.8 105±0.2 
F3 335±3.5 8.25±0.1 21.7±0.3 112.8±1.2 
F4 652±5.5 2.78±0.24 29.33±0.18 51.5±0.6 
F5 20±1.0 13.61±0. 5 4.275±0.2 474.5±0.15 
F6 297±1.5 7.5±0.55 11.5±0.25 212.8±0.2 
F7 345±2.5 15.2±0.27 27.13±0.5 110.7±0.3 
F8 362±3.5 18.2±0.15 29.14±0.66 115±0.65 
F9 270±2.5 7.8±0.3 18.62±0.25 112.5±0.5 
F10 254±1.5 8.1±0.8 17.35±0.45 115.4±0.26 
F11 258±3.65 5.2±0.5 14.4±0.5 110±0.4 
F12 355±2.55 4.39±0.2 25.5±0.3 88±1.1 
F13 358±2.2 4.8±0.8 19.6±0.6 87.3±0.5 
F14 362±1.2 4.9±0.4 18.6±0. 5 86.4±0.25 
SD-Standard Deviation; n=3. 
 
 
Fig. 3: In vitro disintegration time of different film-forming polymers, (All the values were calculated as mean±standard deviation; n=3) 
 
The formula (F1) gave satisfactory % elongation (5.87±0.5%), but it 
gives low folding endurance values (36±0.5), these results were 
recorded by Bhikshapathi DVRN et al. [10]. Also, HPMC E3 film (F1) 
was difficult to handling that is recorded by Kumar SK et al. [25]. 
In the other hand, the films of gelatin (F6) also give low 
disintegration time (20.3±0.2) and with good mechanical properties 
(folding endurance 297) and satisfactory % elongation 
(11.5±0.25%). The problem seen by using this polymer was the hard 
peeling of the film from the petri dish (its peeled as apices) this 
result also reported by T. Hassanien et al. [26] 
While films of PVA (F4) have good mechanical properties with good 
peeling off and good appearance but with long disintegration time 
(61±0.3 sec.) due to the swelling property of this polymer which makes a 
gel-like layer on the surface of the film upon contact with aqueous media 
lead to prevent penetration of water to the film, this swelling property 
increased with increasing of the polymer concentration [27]. 
The films that prepared with pectin as film-forming polymer gave as 
shown in the table (3) a relatively long disintegration time (49.3±0.2 
sec.) with low folding endurance value (20±1) and bad mechanical 
properties (high (percentage of elongation, young's modulus and low 
percentage of elongation) as shown in table (3) this indicates that the 
films were brittle and weak. The reason for the brittle film formation 
was the insufficient concentration of polymer in the formulation [28]. 
While (F2) (HPMC E5) gave satisfactory % elongation (20.86±0.8) 
and good folding endurance values (337±2.5), these outcomes were 
in concurrence with those that reported by Chauhan SS et al. [29].  
On the other hand, the film made from HPMC E15 has acceptable 
mechanical properties, young's modulus (112.8±1.2) and folding 
endurance (335±3.5), but the formulated HPMC E5 film has faster 
disintegration time than HPMC E15 formula (18.6±0.1 and 29±0.5) 
respectively. 
The in vitro dissolution profile of bromocriptine mesylate fast 
dissolving oral films of the formulas (F2 and F3) as shown in fig. (4). 
The values of T80% for the films prepared with HPMC E5 and HPMC 
E15 (F2 and F3) was 2.6 and 4.99 min respectively. The difference in 
the dissolution parameters caused by the variances in viscosity 
grade of HPMC film-forming polymer. These results agree with the 
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result obtained by Pradhan R et al. by using different grades of 
HPMC and studying its effect on the release profile of indomethacin 
and report that drug release decreased with increase in the viscosity 
of polymer used [30]. From results, the disintegration time in mouth 
increased with increasing the viscosity of HPMC polymer and with 
increasing the polymer level in the formulation. 
 
 
Fig. 4: Effect of polymer type on the dissolution profile of bromocriptine mesylate in phosphate buffer (pH 6.8) at 37 °C, (All the values 
were calculated as mean±standard deviation; n=3) 
 
The time needed for 80 % of medication to be released (T80%) and 
percent medication dissolved in 2 min (% D2 min) from the 
formulated films (F2 and F3) are listed in the table (5). From all 
these results we found that the HPMC E5 had the best physical, 
mechanical properties and drug release profile than the other film 
forming polymers. 
 
Table 5: In vitro dissolution considerations of (F2 and F3) 
Formula T80% (min) mean±SD %D2 min mean±SD 
F2 2.6±0.5 71.6±0.2 
F3 4.99±0.15 61.4±0.25 
SD-Standard deviation; n=3; T80%-time required for 80% of drug to be released; %D2 min-cumulative percentage release of drug at 2 min.  
 
Effect of concentrations of selected polymer (HPMC E5) 
According to the physical and mechanical properties and the drug 
release profile, HPMC E5 was selected as an optimized suitable 
polymer for prepare fast dissolving bromocriptine mesylate oral film.  
So formulas (F2, F7, and F8) of different polymer concentrations 
(50%, 55% and 60% w/w) respectively were further evaluated to 
get an optimum suitable polymer concentration by study their 
dissolution profile parameters.  
Table (3) revealed that there is a significantly (p ≤ 0.05) decrease in 
the invitro DT of the formulated strips with the decrease in 
concentration of HPMC E5 from (60% w/w) in formula (F8) to (50% 
w/w) in formula (F2).  
It appears that films containing a high concentration of polymer 
resulted in a thicker gel upon contact with the medium, resulting in 
longer disintegration time as shown in fig. (3). the same result was 
obtained with metoprolol tartrate strips and lamotrigine fast 
dissolving films [31, 32]. 
  
 
Fig. 5: In vitro disintegration time of different concentration of the selected film-forming polymer (HPMC E5), (All the values were 
calculated as mean±standard deviation; n=3) 
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The results of tensile testing listed in the table (4) that indicate high 
tensile strength film result from increasing the polymer concentration, 
this is due to the fact that densely packed chains of HPMC produced 
from increasing polymer concentration, make the film need more force 
to breaks [33]. Same findings were found with valsartan film [34]. 
Also, the results revealed that the percentage elongation and folding 
endurance of the films were increased with an increase in the 
concentration of polymer as in table (4), due to increase in the 
elasticity nature of the polymer [28]. Similar observations were 
found by Trivedi J et al. [35]. 
Table (6) shows that the formula (F2) has the highest D2 min (%) and 
the lowest T80% (min) (2.6 min) indicate that F2 which contain the 
lowest percent of polymer (50 % HPMC E5) gave fastest dissolution 
rate compared with the other formulas (F7and F8) as shown in fig. (6). 
From the dissolution parameters that showed in table (6) for the 
formulas prepared with a different concentration of the selected 
polymer HPMC E5 (F2, F7 and F8) which contain (50%, 55% and 
60% w/w respectively), it was seeing that the dissolution rate of 
bromocriptine mesylate reduces significantly (p<0.05) as the 
concentration of HPMC E5was increase from 50 % (w/w) in formula 
(F2) to 60 % (w/w) in formula (F8) as shown in fig. (6), this results 
may be due to that higher concentration of polymer, results in the 
production of high consistency gel layer created by the close 
interaction between the particles of HPMC E5 results in a diminished 
movement of medication particles in swollen lattices, which 
prompts a decline in dissolution rate [33]. 
Therefore, HPMC E5 (50 % w/w) was considered as the best 
polymer concentration and was chosen for the design of the 
subsequent formulas through the study. 
 
Table 6: In vitro dissolution parameters from the prepared oral films (F2, F7, and F8) 
Formula code T80%(min) mean±SD D2 min(%) mean±SD 
F2 2.6±0.5 71.6±0.2 
F7 4.7±0.25 60.5±0.55 
F8 5.29±0.3 53.7±1.25 
SD-Standard deviation; n=3; T80%-time required for 80% of drug to be released; %D2 min-cumulative percentage release of drug at 2 min.  
 
 
Fig. 6: Cumulative percent of bromocriptine mesylate release of different concentration of HPMC E5 in phosphates buffer (pH 6.8) at 37 °C, 
(All the values were calculated as mean±standard deviation; n=3) 
 
Effect of the type and concentration of plasticizers 
Formulas (F2, F9 and F10) were employed to study the effect of 
different plasticizer types in concentration 20% w/w (glycerin, PEG 
400 and PG) and different concentration of PEG 400 (20, 20 and 25 
% w/w) in formulas (F2, F11 and F12) on the mechanical, physical 
properties and on the dissolution profile of the bromocriptine 
mesylate FDOFs. 
The results showed that changing of plasticizer type caused no 
significant effect (p>0.05) on the in vitro DT of mouth dissolving 
strips, as show in fig. (7), this may be due to the fact that three types 
of plasticizer enhanced the disintegration time by facilitating the 
penetration of fluids into the strip, since plasticizer alter the densely 
packed chains of HPMC texture by forming a polymer structure 
possess more pores and less densely that breaks at lower force, 
resulting in faster disintegration of the film [36]. 
The folding endurance of formulation with PEG 400 as a plasticizer 
were higher compared to other plasticizers. The same result was 
obtained with diazepam oral strips [37]. On the other hand, HPMC 
films that plasticized with propylene glycol were patchy and sticky 
in appearance, while glycerin made soft and tough strips. At the 
same time, films plasticized with PEG 400 exhibited good physical 
and mechanical properties such as tensile strength and percentage 
of elongation as shown in the table (4). These observations are in 
accordance with Choudhary et al. [38] and Ali MS et al. [37]. So 
PEG400 was selected for further study of suitability in films 
formulation. 
The time needed for 80% of medication to be released (T80%) and 
percent medication dissolved in 2 min (D2 min) from the formulated 
films (F2, F9, and F10) are listed in the table (7). 
The release profile of bromocriptine mesylate from formulas (F2, 
F9 and F10) which contain 20 % w/w of (PEG 400, PG and 
glycerin) respectively is displayed in fig. (8). It was seen that 
changing the plasticizer types had no-significant change (p>0.05) 
on the dissolution profile of bromocriptine mesylate, this may be 
because of that the three plasticizers are water dissolvable and 
they will diffuse out from the films in watery media making void 
spots in the film through which distribution of liquid happens to 
enable film breaking down leading to improve release profile of 
drug [39]. 
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Fig. 7: In vitro disintegration time in seconds of formulas prepared with different types of plasticizer, (All the values were calculated as 
mean±standard deviation; n=3) 
 
Table 7: In vitro dissolution parameters from the prepared oral films (F2, F9, and F10) 
Formula code T80% (min) mean±SD D2 min (%) mean±SD 
F2 2.6±0.5 71.6±0.2 
F9 2.9±0.2 69.4±0.55 
F10 3.0±0.15 68.8±0.8 
SD-Standard deviation; n=3; T80%-time required for 80% of drug to be released; % D2 min-cumulative percentage release of drug at 2 min.  
 
 
Fig. 8: Cumulative percent of bromocriptine mesylate release from formulas prepared with the different type of plasticizers in phosphates 
buffer (pH 6.8) at 37 °C, (All the values were calculated as mean±standard deviation; n=3) 
 
Formulas F2, F11, and F12 were used to study the effect of different 
concentrations of selected plasticizer PEG400 (20, 15 and 25 %w/w 
of the total film weight) on the in vitro disintegration time, 
mechanical properties and the drug release profile of the oral film. 
  
 
Fig. 9: In vitro disintegration time in seconds of formulas prepared with the different concentration of the selected plasticizer (PEG 400), 
(All the values were calculated as mean±standard deviation; n=3) 
 
Different concentration of PEG400 (20, 15 and 25 %) which present 
in formulas (F2,F11 and F12) show a decrease in disintegration time 
as the plasticizer concentration increased as shown in fig. (9) this 
occurs because PEG 400 act as a co-solvents that reduce the ability 
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of water to squeeze out non-polar, hydrophobic compounds, thus 
increasing solubility [40]. 
The mechanical properties of formulas (F2, F11, and F12) are shown 
in the table (4), which shows that the increase in the plasticizer 
concentration produced a decrease of the Young's modulus (YM), 
and the tensile strength (TS). The decrease in tensile strength as a 
function of plasticizer concentration increase may be due to the 
weakening of the intermolecular forces between polymer chains, 
thus leading to decrease the rigidity of three-dimensional structure 
formed upon drying the film, this leads to a less force to break the 
film. Moreover, it was seen that the increasing the concentration of 
plasticizer leading to increasing the percentage of elongation (%E). 
These results can be explained by the fact that the plasticizers act as 
an interior emollient and enhance movement of the polymer chains 
(lubricity theory) [41]. 
From the release profile of bromocriptine mesylate from formulas 
(F2, F11, and F12) which contain 20, 15 and 25% of PEG 400 
respectively that shown in (fig. 10), it was observed that the drug 
release rate increased significantly (p<0.05) as the concentration 
PEG 400 was increased; Here the role of PEG 400 may be a 
dissolution facilitating agent, therefore increasing concentration will 
increases the drug release rate [42]. 
The time needed for 80% of medication to be released (T80%) and 
percent medication dissolved in 2 min (D2 min) from the formulated 
films (F2, F11and F12) are listed in the table (8).  
The dissolution parameters showed that F12 prepared with 25% 
PEG400 had the best drug release profile among other formulas 
prepared with less concentration of PEG400, so F14 was chosen for 
the design of the subsequent formulas through the study. 
 
Table 8: In vitro dissolution parameters from the prepared oral films (F2, F11, and F12) 
Formula code T80%(min) mean±SD D2 min(%) mean±SD 
F2 2.6±0.5 71.6±0.2 
F11 3.14±0.3 65.4±0.8 
F12 2.06±0.25 77.4±0.65 
SD-Standard deviation; n=3; T80%-time required for 80% of drug to be released; % D2 min-cumulative percentage release of drug at 2 min.  
 
 
Fig. 10: Cumulative percent of bromocriptine mesylate release from formulas prepared with the different concentration of PEG400 in 
phosphates buffer (pH 6.8) at 37 °C, (All the values were calculated as mean±standard deviation; n=3) 
 
Effect of super-disintegrant (crospovidone) concentration 
Incorporation of super-disintegrant (crospovidone) to the best formula 
(F12),from the previous study, in different concentrations (1 and 3% 
w/w) of the total dry weight of the film represented by (F13 and F14) 
respectively to study its effect on the physical, mechanical properties and 
the release profile of bromocriptine mesylate from the film. 
The physical properties in the table (3) showed an enhancement in 
the disintegration time also shown in fig. (11) with the addition of 
crospovidone to the prepared formula also the disintegration time 
was more enhanced with increasing the concentration of 
crospovidone from 1% to 3% w/w as shown in (F13 and F14) 
respectively. This disintegration enhancement is caused by the 
ability of crospovidone to wick saliva quickly into the film that leads 
to generate the volume expansion and hydrostatic pressures 
necessary to provide rapid disintegration in the mouth, the major 
mechanism of disintegration for crospovidone is wicking mechanism 
in addition to the swelling mechanism [43]. 
  
 
Fig. 11: In vitro disintegration time in seconds of formulas prepared with a different concentration of supper disintegrant (crospovidone), 
(All the values were calculated as mean±standard deviation; n=3) 
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While the mechanical properties for related parameters (percentage 
of elongation, tensile strength, and Young's modulus) as shown in 
the table (4) which revealed that there is no significant difference 
(P>0.05) with the addition of crospovidone. 
On the other hand, adding crospovidone in F13 and F14 (1% and 3% 
respectively) to the prepared bromocriptine mesylate fast dissolving 
films show a significant difference (p<0.05) in the dissolution release 
profile in compares with (F12) prepared without crospovidone as 
represented by the fig. (12). This result also reported by Deep AK and et 
al. were they got an increase in disintegration and enhance in dissolution 
release profile of cinnarizine fast dissolving films by increasing the 
amount of crospovidone [44]. The release of bromocriptine mesylate 
mainly depends upon the superdisintegrant concentration. It was found 
that increase in the content of superdisintegrants, increased the drug 
release [45]. The enhancement in the release of drug from F13 and F14 
can be explained by the porous structure of crospovidone in which the 
crospovidone particles seem to be granular and highly porous when 
examined under a scanning electron microscope. This unique, porous 
particle morphology is acting to wick the liquid, and due to its high 
crosslink density leading to fast swelling of crospovidone in water 
without gelling [46]. 
 
 
Fig. 12: Cumulative percent of bromocriptine mesylate release from formulas prepared with the different concentration of crospovidone 
in phosphates buffer (pH 6.8) at 37 °C, (All the values were calculated as mean±Standard Deviation; n=3) 
 
The time needed for 80% of medication to be released (T80%) 
and percent medication dissolved in 2 min (% D2 min) from the 
formulated fast dissolving oral films (F12, F13and F14) are 
listed in table (9), which showed that F14 (3% crospovidone) 
gave the fastest T80% (1.35±0.3) and the highest %D2 min 
(86.8±0.1).
 
Table 9: In vitro dissolution parameters from the prepared oral films (F12, F13, and F14) 
Formula code T80% (min) mean±SD D2 min (%) mean±SD 
F12 2.06±0.25 77.4±0.65 
F13 2.0±0.1 78.9±0.2 
F14 1.35±0.3 86.8±0.1 
SD-Standard deviation; n=3; T80%-time required for 80% of drug to be released; % D2 min-cumulative percentage release of drug at 2 min, 
according to the results above, F14 was selected as an optimized formula for the formulation of bromocriptine mesylate fast dissolving oral film.  
 
 
Fig. 13: FTIR spectrum of bromocriptine mesylate 
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Drug-polymer compatibility study 
Fourier transform infrared spectroscopy (FTIR) 
The principal peaks of the FT-IR spectrum of bromocriptine 
mesylate are shown in fig. (13), which is at the wave numbers(in cm-
1):1047 for alcohol C-H stretching (1260-1000), 1211 for alkyl 
halide C-Br wagging band (1300-1150), 1361 for the S=O in 
sulphonate salt (1372-1335), 1444 for aromatic ring (1500-1400), 
1544 for amide N-H (1650-1515), two bands 1726 and 1672 for C=O 
stretching in the ketone group (1870-1540), and 3261 for amide N-
H stretching (3350-3180) [47]. 
Similar peaks were obtained from the bromocriptine in the physical 
mixture of the selected formula 14 and in the selected formula (F 
14) as a film as shown in fig. 13, 14 and fig. 15 respectively, this 
indicates the lack the possibility of interaction between drug and 
excipients used in the preparation. 
 
 
Fig. 14: FTIR spectrum of a physical mixture of the selected formula (F14) 
 
 
Fig. 15: FTIR spectrum film of the selected formula (F14) 
 
X-Ray diffraction  
The x-ray diffractogram of bromocriptine mesylate confirms its 
crystalline nature, as evidenced by the number of sharp and 
intense peaks as shown in fig. (16). However, the diffraction 
pattern of selected formula F14 represents disappearance of 
crystalline peaks of the drug, and these findings suggest the 
improvement of drug solubility by the formation of an amorphous 
form of the drug. Similar results were observed by Reddy PB et al. 
[48]. 
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Fig. 16: A. X-Ray diffraction of pure bromocriptine mesylate, B. X-Ray diffraction of the selected formula F14 
 
CONCLUSION 
By the results obtained; hydroxypropyl methylcellulose showed the 
fastest in vitro disintegration time. In addition, acceptable mechanical 
properties and dissolution behaviour were achieved. Also, PEG400 
was the best plasticizer as it showed an improvement in mechanical 
and physical characteristics of the bromocriptine mesylate oral film. 
Formula (F14) which composed from 50% w/w HPMC E5 as a film 
forming polymer, 25% PEG400 as a plasticizer, 5% poloxamer 407 as 
a surfactant and 3% crospovidone as superdisintegrant regarded as an 
optimized formula with a low disintegration time (9.2±0.1 seconds), 
80% of drug released within (1.35 minute). 
Bromocriptine mesylate administered in the form of fast dissolving 
films will be a potential novel drug dosage form for geriatric and 
also for the general population with DM type II by providing faster 
release and better patient compliance. 
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